Skip to content

Psychedelic-assisted therapy: all studies

Page 263 of 294: studies 2,621 to 2,630 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

What Can the Chemical Hold?: The Politics of Efficacy in the Psychedelic Renaissance.

Culture, Medicine, and Psychiatry March 2, 2021 Katherine Hendy

Drawing from ethnographic research with psychedelic therapists and researchers, this article explores political tensions between two sources of efficacy within psychedelic therapy: the self and the chemical. At times researchers and therapists emphasize the specificity of chemical effects in relationship to the neurobiology of particular diagnoses. And at other times they foreground the self as...

DOI: 10.1007/s11013-021-09708-7 (opens in new tab) Full text (opens in new tab) Humans Hallucinogens Restraint, physical Politics +4

Session on Psychedelics Sure to Be Enlightening

Psychiatric News March 1, 2021 Nick Zagorski

Back to table of contents Previous article Next article APA & MeetingsFull AccessSession on Psychedelics Sure to Be EnlighteningNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:2 Mar 2021https://doi.org/10.1176/appi.pn.2021.3.14AbstractLeaders in psychedelic research will discuss the therapeutic potential of psychedelic compounds in psychiatry and important...

The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges

Risk Management and Healthcare Policy March 1, 2021 Rafael G. Dos Santos, José Carlos Bouso, Juliana Mendes Rocha et al. 58 citations

Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT2A receptors as their main mechanism of action. Its main effects include changes in perception, cognitive process, and mood. Despite being used for centuries by different cultures in ritual contexts, these substances have currently aroused the interest of science and industry for...

Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2

The Journal of Clinical Psychiatry February 23, 2021 Avinash Hosanagar, Joseph Cusimano, Rajiv Radhakrishnan 1 citation

P sychedelics have recently gained attention as compounds with therapeutic potential in the treatment of psychiatric disorders.The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designations for (±)-3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy in severe posttraumatic stress disorder (PTSD) (in 2017) and for the adjunctive use of psilocybin with...

The Evolved Psychology of Psychedelic Set and Setting: Inferences Regarding the Roles of Shamanism and Entheogenic Ecopsychology

Frontiers in Pharmacology February 23, 2021 Michael Winkelman 62 citations

This review illustrates the relevance of shamanism and its evolution under effects of psilocybin as a framework for identifying evolved aspects of psychedelic set and setting. Effects of 5HT2 psychedelics on serotonin, stress adaptation, visual systems and personality illustrate adaptive mechanisms through which psychedelics could have enhanced hominin evolution as an environmental factor...

DOI: 10.3389/fphar.2021.619890 (opens in new tab) Shamanism Consciousness Cognitive psychology Cognitive science +1

How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence

Anesthesia & Analgesia February 17, 2021 Peter G. Brindley 49 citations

It is tough to write about psychedelics without a few gratuitous puns. Regardless, Michael Pollan’s “How to Change Your Mind” is definitely “mind expanding” and deserves my “highest” recommendation. Published in 2019, this book comprehensively and presciently covers a topic of increasing interest: whether psychedelic agents can revolutionize mental health. Pollan is not a Medical Doctor but is...

DOI: 10.1213/ane.0000000000005349 (opens in new tab) Psilocybin Counterculture Consciousness Psychic +4

The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of ketamine and metabolites

February 13, 2021 Philip E. Wolfson, Rob Cole, Kara L. Lynch et al. 5 citations

Abstract: There is no available data on the secretion and concentration of ketamine and its metabolites in breastmilk. There are statements in the literature made as to the safety of the use of ketamine in lactating women, though these are unsupported. This information is pertinent for the treatment of breastfeeding women who may have depression, PTSD, postpartum depression, and other emotional...

Cannabinoids is a “No-Go” While a Cancer Patient is on Immunotherapy; but is It Safe to Use Psychedelics During Cancer Immunotherapy?

bioRxiv (Cold Spring Harbor Laboratory) February 2, 2021 E. Amit Romach, M. Nachliely, Olivia Moran et al. 2 citations preprint

Abstract The use of Psychedelics by patients with cancer to relieve anxiety and depression has increased in the past few years. Since Psychedelics have immunomodulatory effects, their consumption among cancer patients should be carefully considered due to their potential negative effects on the tumor immune stroma, especially in view of the increase in the utilization of therapeutic approaches...

DOI: 10.1101/2021.02.01.429102 (opens in new tab) Full text (opens in new tab) Anxiety Immune system Cancer immunotherapy Depression economics +1

Psychedelic‐assisted therapy for functional neurological disorders: A theoretical framework and review of prior reports

Pharmacology Research & Perspectives February 2, 2021 Benjamin J. Stewart, Jon G Dean, Adriana Koek et al. 15 citations

Abstract Functional neurological disorders (FNDs), which are sometimes also referred to as psychogenic neurological disorders or conversion disorder, are common disabling neuropsychiatric disorders with limited treatment options. FNDs can present with sensory and/or motor symptoms, and, though they may mimic other neurological conditions, they are thought to occur via mechanisms other than...

DOI: 10.1002/prp2.688 (opens in new tab) Full text (opens in new tab) Serotonin Hallucinogens Psychosomatic medicine Receptor +9

Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial.

Journal of Psychopharmacology February 1, 2021 Rebecca L Rothberg, Nour Azhari, Nancy A Haug et al. 95 citations

Sub-anesthetic ketamine administration may be helpful for substance use disorders. Converging evidence suggests that the efficacy of ketamine for certain conditions may implicate a subset of its psychoactive effects. The aim of this analysis is to evaluate whether the mystical-type effects of ketamine are critical for clinical efficacy in alcohol-dependent individuals. In this secondary...